Marco Meglio

The authors noted that research is still needed to establish standards for cell mobilization and immune-conditioning regimens.

The professor of neurology at the NYU Langone Grossman School of Medicine discussed a recent study she and colleagues conducted on new neurological disorders in patients with COVID-19.

The FDA told Xeris that it could advance diazepam directly into a phase 3 registration study for both pediatric and adult patients with epilepsy after reviewing phase 1b results.

Zosano plans to request a Type A meeting with the FDA to discuss strategies to address the FDA’s comments regarding the new drug application.

On the heels of successful long-term data, evobrutinib seeks to maintain its high efficacy in 2 pivotal phase 3 clinical trials.

Statistically significant worsening on the Epworth Sleepiness Scale was observed in patients randomized to placebo compared to participants who received JZP-258.

Study results suggest daxibotulinumtoxinA has the potential to reduce the frequency of cervical dystonia treatments by up to 50% annually.

Elias Kouchakji, MD, provides details of the phase 3 LELANTOS study of novel antibody pamrevlumab for the treatment of Duchenne muscular dystrophy.

The use of real-time quaking-induced conversion and protein misfolding cyclic amplification assays accurately allowed researchers to differentiate synucleinopathies from nonsynucleinopathies.

Decreases in weekly migraine days remained steady during the last 2 weeks of the first quarter, with a similar maintenance of response during the second quarter.

Patients with neurologic disorders were more often older, male, white, hypertensive, diabetic, intubated, and had higher sequential organ failure assessment scores.

Italfarmaco is expected to report topline data from the phase 3 EPYDIS trial in June 2022.

The largest real-world study of patient-reported outcomes in people with migraine demonstrated the positive benefits that the CGRP mAbs drug class has had on migraine.

Topiramate oral solution is Eton’s third neurology product candidate submitted to the FDA, this time seeking 3 indications.

Investigators noted changes in plasma vascular endothelial growth factor and S100 ß levels indicate a protection-based mechanism derived from the combined treatment.

Patients on lasmiditan had 3.8–7.2 times greater odds of achieving pain freedom at 2 hours compared to placebo in at least 2 out of 3 migraine attacks.

Phase 2 results demonstrated proof-of-concept for treatment with neflamapimod, suggesting the need for a phase 3 study in the coming future.

The upcoming phase 2b/3 study of mesdopetam in patients with Parkinson disease is set after the results of previous successful phase 1, phase 2a, and phase 2 studies.

Nearly two-thirds of patients achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10.6 months.

James Leverenz, MD, director of the Lou Ruvo Center for Brain Health at Cleveland Clinic, discussed the strides made in Alzheimer disease research and the importance of diversity in research populations.

Linear mixed effects models revealed that anticholinergic medications predicted a steeper slope of decline in memory and language with effects exacerbated in individuals with Alzheimer disease risk factors.

The Clinical Global Impression of Change and Caregiver Global Impression of Change scores suggest improvements extending beyond motor seizure frequency reduction in both patients with CDD and Dup15q.

The results confirmed that roughly almost 15% of cases are linked to genes and ultimately led to recommendations for more tailored treatments of 3 patients.

Jonathan Graff-Radford, MD, neurologist at Mayo Clinic, discussed how recent diagnostic advancements have propelled research efforts into uncharted territory.

The use of statins was also associated with a reduced risk of SUDEP, but there were no reduced risks with SSRIs or other antidepressants, neuroleptics, or beta-blockers.

The primary objective of the trial is to demonstrate that lorcaserin has superior efficacy compared to placebo as measured by percent change in frequency of convulsive seizures per 28 days.

The findings were consistent with the drug's previously reported safety profile and no new safety signals were observed.

The funding will offer additional benefit for the HABLE and HABLE-AT(N) studies with the ability to better classify and categorize participants into groups by dementia type and disease stage.

The vaccine could be given therapeutically to individuals living with a diagnosis of AD to inhibit further disease progression.

The study investigators noted that a higher gravidity and parity number was not associated with a delay in CIS onset.